2-氟-5-(三氟甲氧基)苯腈 | 886498-08-4

• 物质功能分类: 有机原料 - 有机氟化合物 - 氟苯腈系列
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 2-氟-5-(三氟甲氧基)苯腈
• 中文别名: 2-氟-5-三氟甲氧基苯甲腈
• 英文名称: 2-fluoro 5-(trifluoromethoxy)benzonitrile
• 英文别名: 2-fluoro-5-(trifluoromethoxy)benzonitrile；2-fluoro-5-trifluoromethoxy-benzonitrile
• CAS: 886498-08-4
• 化学式: C₈H₃F₄NO
• mdl: MFCD04115894
• 分子量: 205.112
• InChiKey: MFLGNKVMGUFLOV-UHFFFAOYSA-N

物化性质

• 沸点：
  189.3±40.0 °C(Predicted)
• 密度：
  1.42±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  33
• 氢给体数：
  0
• 氢受体数：
  6

安全信息

• 危险等级：
  6.1
• 海关编码：
  2926909090
• 包装等级：
  III
• 危险类别：
  6.1
• 危险品运输编号：
  UN3276
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  密封保存，置于干燥处并在室温环境下保存。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-Fluoro-5-(trifluoromethoxy)benzonitrile
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H331: Toxic if inhaled
H302: Harmful if swallowed
H312: Harmful in contact with skin
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
P280: Wear protective gloves/protective clothing/eye protection/face protection
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P304+P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P405: Store locked up

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-Fluoro-5-(trifluoromethoxy)benzonitrile
CAS number: 886498-08-4

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C8H3F4NO
Molecular weight: 205.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen fluoride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
UN Number: UN3276 Class: 6.1 Packing group: III
Proper shipping name: NITRILES, TOXIC, LIQUID, N.O.S. (2-Fluoro-5-(trifluoromethoxy)benzonitrile)

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-氟-5-(三氟甲氧基)苯腈 在 乙醇 、 ammonium acetate 、 sodium cyanoborohydride 、 (benzotriazo-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate 、 N,N-二异丙基乙胺 作用下， 以 乙醚 、 N,N-二甲基甲酰胺 为溶剂， 反应 74.08h， 生成 5-{2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl}-N-{1-[2-fluoro-5-(trifluoromethyl)phenyl]ethyl}-2-methylpyridine-3-carboxamide
  参考文献：
  名称：

  [EN] AMINOTRIAZOLOPYRIDINES AS KINASE INHIBITORS
  [FR] AMINOTRIAZOLOPYRIDINES UTILISÉES EN TANT QU'INHIBITEURS DE KINASE

  摘要：

  具有化学式（I）（IX）的化合物，以及其对映体、非对映体、立体异构体、药学上可接受的盐和前药，可用作激酶调节剂，包括RIPK1调节。所有变量的定义如下：（I）、（II）、（III）、（IV）、（V）、（VI）、（VII）、（VIII）、（IX）。

  公开号：

  WO2018148626A1
• 作为产物：
  描述：

  E-2-fluoro-5-trifluoromethoxy-benzaldehyde oxime 在 三乙胺 、 三氟乙酸酐 作用下， 以 四氢呋喃 为溶剂， 反应 1.0h， 以83%的产率得到2-氟-5-(三氟甲氧基)苯腈
  参考文献：
  名称：

  Substituted imidazo[1,5-A][1,2,4]triazolo[1,5-D][1,4]benzodiazepine derivatives

  摘要：

  本发明涉及公式I的取代咪唑[1,5-a][1,2,4]三唑[1,5-d][1,4]苯二氮杂环己烷衍生物，其中R1为氢、卤素、较低烷基、被卤素取代的较低烷基、较低烷氧基、被卤素取代的较低烷氧基、硝基、环烷基、—O(CH2)mO(CH2)mOH或—C≡C—R′；R2为氢或甲基；R3为较低烷基、被卤素取代的较低烷基、较低烯基、被卤素取代的较低烯基、较低炔基、—(CH2)n-环烷基、—(CR′R″)m—CH3、苯基（未取代或被卤素取代）、吡啶基或噻吩基，每种基未取代或被较低烷基取代、—(CH2)n—NH-环烷基、较低烯基-环烷基、较低炔基-(CR′R″)mOH或较低炔基-苯基，其中苯环未取代或被卤素、CF3、较低烷基或较低烷氧基取代；R′为氢或较低烷基；R″为氢、羟基或较低烷基；n为0、1或2；m为1、2或3；o为1或2；及其药学上可接受的酸盐。这类化合物对GABA A α5受体结合位点具有高亲和力和选择性。因此，该发明还涉及增强认知和治疗像阿尔茨海默病这样的认知障碍的方法。

  公开号：

  US20060128691A1

文献信息

• Synthesis and Structure-Activity Relationship Studies of 2-(1,3,4-Oxadiazole-2(3<i>H</i>)-thione)-3-amino-5-arylthieno[2,3-<i>b</i>]pyridines as Inhibitors of DRAK2
  作者：Piotr Leonczak、Ling-Jie Gao、Anna Teresa Ramadori、Eveline Lescrinier、Jef Rozenski、Steven De Jonghe、Piet Herdewijn

  DOI：10.1002/cmdc.201402234

  日期：2014.11

  recent years, DAPK‐related apoptosis‐inducing protein kinase 2 (DRAK2) has emerged as a promising target for the treatment of a variety of autoimmune diseases and for the prevention of graft rejection after organ transplantation. However, medicinal chemistry optimization campaigns for the discovery of novel small‐molecule inhibitors of DRAK2 have not yet been published. Screening of a proprietary compound

  近年来，DAPK相关的凋亡诱导蛋白激酶2（DRAK2）已成为治疗各种自身免疫性疾病和预防器官移植后移植排斥的有希望的靶标。但是，尚未发现用于发现DRAK2新型小分子抑制剂的药物化学优化方案。导致了苯并噻吩类似物的发现专有化合物文库的筛选，其中显示的亲和常数（ķ d 0.25μ）值中号。芯支架的变化时，可以得到一系列5- arylthieno [2,3-的取代模式的b ]与强的结合亲和力的吡啶（ķ d = 0.008μ中号代表最有力的代表）。这些化合物还显示出在功能生化DRAK2酶测定有前途的活性，与IC 50值的0.029μ中号为最有效的同类。最有效的化合物的选择性分析表明，它们在DAPK激酶家族中缺乏选择性。但是，效力较低的类似物之一是DRAK2的选择性配体，可以用作合成选择性有效的DRAK2抑制剂的起点。
• [EN] COMPOUNDS<br/>[FR] COMPOSÉS
  申请人：CTXT PTY LTD

  公开号：WO2019243491A1

  公开（公告）日：2019-12-26

  A compound of formula (I), or a pharmaceutical salt thereof.

  式(I)的化合物，或其药用盐。
• [EN] ANTIBACTERIAL COMPOUNDS HAVING BROAD SPECTRUM OF ACTIVITY<br/>[FR] COMPOSÉS ANTIBACTÉRIENS À LARGE SPECTRE D'ACTIVITÉ
  申请人：ACRAF

  公开号：WO2016096686A1

  公开（公告）日：2016-06-23

  The present invention relates to novel antibacterial compounds, pharmaceutical compositions containing them and their use as antimicrobials.

  本发明涉及新型抗菌化合物，含有它们的药物组合物以及它们作为抗微生物药物的用途。
• CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2
  申请人：Zhang Xuqing

  公开号：US20110306592A1

  公开（公告）日：2011-12-15

  The present invention comprises compounds of Formula (I). wherein: R 1 , R 2 , X, and Z are as defined in the specification. The invention also comprises a method of preventing, treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is type II diabetes, obesity and asthma. The invention also comprises a method of inhibiting CCR2 activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula (I).

  本发明包括式(I)的化合物。其中：R1、R2、X和Z如规范中所定义。该发明还包括一种预防、治疗或改善综合症、紊乱或疾病的方法，其中所述综合症、紊乱或疾病为II型糖尿病、肥胖和哮喘。该发明还包括通过给哺乳动物施用至少一种式(I)化合物的治疗有效量来抑制CCR2活性的方法。
• Iminopyridine Derivatives and Use Thereof
  申请人：YOSHIDA MASATO

  公开号：US20090270393A1

  公开（公告）日：2009-10-29

  The present invention aims to provide an iminopyridine derivative compound having an α 1D adrenergic receptor antagonistic action, which is useful as an agent for the prophylaxis or treatment of a lower urinary tract disease and the like. The present invention provides a compound represented by the formula wherein each symbol is as defined in the specification, or a salt thereof.

  本发明旨在提供一种具有α1D肾上腺素受体拮抗作用的咪唑啉衍生物化合物，该化合物可用作预防或治疗下尿路疾病等疾病的药剂。本发明提供了一种由下式表示的化合物或其盐：其中每个符号如规范中定义。